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ABSTRACT: 
 
Group III metabotropic glutamate receptors (mGluR III) are known to decrease glutamate 
release and to play an important role in controlling pain as documented in neuropathic pain 
models. Much less is known about their potential neuroprotective effect against excitotoxicity 
that is considered important for damage onset of spinal cord injury. Using rat spinal cord 
organotypic slices model, we investigated if mGluR III receptor activation might contrast 
excitotoxic cell death evoked by kainic acid (0.1 mM) applied for 1h and followed by wash 
for further 24h. The specific agonist of mGluR III receptors L-(+)-2-amino-4-
phosphonobutyric acid (L-AP4; 1 µM) was either co-applied with kainic acid or administered 
during washout. Cell death was quantified in terms of percentage of pyknotic nuclei, total 
number of neurons, motoneurons and astrocytes.  
Furthermore we developed for future long-term studies an in vitro model of Spinal Cord 
Isolated from newborn rats maintained for 3 days in medium. We characterize this model 
using both immunohistochemistry and electrophysiological recordings. 
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CHAPTER 1:  INTRODUCTION 
 
1.1 SPINAL CORD INJURY 
 
Spinal Cord Injury (SCI) is an event related to severe damage to spinal cord that leads to 
loss of sensory and motor function distal to the point of injury (Hulsebosch 2002). SCI can 
be traumatic or non-traumatic, producing long-term effects, severe lifelong disabilities that 
are very problematic for the person affected, but also for their family and society (M. E L Van 
Den Berg et al. 2010). The Annual Incidence of SCI estimated in 22 new cases every millions 
of population and there are ~2.5 million people affected by SCI (Rossignol et al. 2007). The 
average age of the patients is 31.7 years and the ratio between male and female is four to 
one (John W. McDonald and Sadowsky 2002). Life expectancy in spinal cord injured people 
increased from World War II (3 months) to now (25 to 30 years) (Hulsebosch 2002). One or 
more of the following symptoms may characterize SCI: paralysis, loss of the possibility to 
feel cold, heat and touch, hyper-reflexia or spasm, pain, loss of bladder control, loss of 
sexual functions. The spinal cord is divided in several segments; starting from the upper to 
the lower, they are cervical, thoracic, lumbar and sacral. Every segment connects to a 
specific part of the body (e.g. cervical are related to respiratory movements) consequently, 
depending on which segment is injured different muscles, organs and sensation are 
involved. Paralysis can be tetraplegia (or quadriplegia), when the level of injury is above the 
first thoracic vertebra (T1), or paraplegia, when the level of injury is below the T1 (Figoni 
1984; Harkey et al. 2003). Significant improvements have been made on repair and recovery 
of function and in the early medical and surgical management. The major therapeutic goal 
during the rehabilitation of patients is to regain a far-reaching autonomy, which involves 
compensation of the disturbed or missing vegetative and sensorymotor functions. Clinically, 
spinal cord injury leads to a complete loss of motor, sensory and vegetative functions 
underneath the point of injury. In this phase of the spinal shock, the vasomotor and visceral 
motor innervation is distrupted. This results not only in tachycardiac/bradicardiac arrhythmia 
but also in hypotensive and hyperextensive episodes/dysregulation (so called autonomic 
dysreflexia). In addition atony of the efferent urine ducts, the stomach and the intestine along 
with paralytic ileus symptoms, endocrine disruptions like hyperglycemia and derailment of 
the electrolyte metabolism and malfunction of the body temperature control occur (Gerner 
1992; Teasell et al. 2000). Upon the decline of the spinal shock, about 4-6 weeks after the 
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initial accident, pathological reflexes and usually also spasticity develop due to the absence 
of supraspinal control (Ditunno et al. 2004). Looking at past research, there are a lot of 
different pathways that have been explored to describe the pathophysiological development 
of secondary damage in SCI and the intrinsic regenerative response. Different studies 
focused on neuronal and glia protection using different pharmacological approaches, from 
methylprednisolone to cyclooxygenase (Hurlbert 2001; Hurley et al. 2002; Schwab et al. 
2004; Short et al. 2000), then the recently discovered EPO and riluzole (Celik et al. 2002; 
Cifra et al. 2012; Gorio et al. 2002). Another field is related to neurorestoration with 
promotion of axonal conduction (Nashmi and Fehlings 2001), remyelination (Bunge 2001; J 
W McDonald 1999; J W. McDonald and Howard 2002), regeneration/plasticity, elimination 
of the inhibitor factors(Schwab et al. 2005). Further groups focused on the environment near 
the lesion site studying the role of scar inhibition (Grimpe and Silver 2002; De Winter et al. 
2002), the blocking of the inhibitory axonal signal integration into the axon (Dergham et al. 
2002; Fournier et al. 2003) and in the end the stimulation of axons via growth factors such 
as neurotrophins (J W. McDonald and Howard 2002). A lot of these studies started from 
previous work on brain injury and are only the first approach on the pathophysiology of the 
Spinal Cord Injury (SCI). The time has come to move further by investigating the 
pathophysiology of the SCI that at the present day remains largely unknown and there are 
no effective treatments to restore completely motor performance after SCI (Rossignol et al. 
2007; Rowland et al. 2008).  
1.2 EPIDEMIOLOGY OF SCI. 
1.2.1 Complete and incomplete SCI 
SCI can be complete or incomplete from a clinical point of view (Harkey et al. 2003). The 
clinical scale established by American Spinal Injury Association (ASIA) divides persons 
affected by SCI in five clusters. From A to E due to severity of neurological loss evaluated 
by verifying the remaining movement abilities of the person injured: 
 
A) Complete. No sensory or motor function is preserved in the sacral segments S4-5. This 
will result in complete paraplegia or tetraplegia. 
B) Sensory Incomplete. Sensory but not motor function is preserved below the neurological 
level and includes the sacral segments S4-5 and no motor function is preserved more than 
three levels below the motor level on either side of the body.  
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C) Motor Incomplete. Motor function is preserved below the neurological level, and more 
than half of key muscle functions below the neurological level of injury have a muscle grade 
less than 3. 
D) Motor Incomplete. Motor function is preserved below the neurological level, and at least 
half of key muscle functions below the neurological level of injury have a muscle grade more 
than 3. 
E) Normal. Sensory and motor functions are normal, in all segments. 
(http://www.asia-spinalinjury.org/elearning/ISNCSCI_ASIA_ISCOS_low.pdf). 
 
1.2.2 Traumatic SCI 
The National Spinal Cord Injury Statistical Center (NSCISC) report for 2014 underlines that 
in the United States the three leading causes of spinal cord injury before 2013 were 
traumatic (figure 1.1). Vehicular accidents, including cars and motorcycles, ranked as the 
leading cause of SCI (38%), even if there was a steady decrease in this percentage of SCI 
causes from 46.9% (1990-1994) to 38%(2013). Falls ranked second (30%) followed by acts 
of violence, primarily gunshot wounds (14%). A decrease in the percentage of SCI due to 
sports-related activities from 14.4 to 9% occurred during the last twenty years. There has 
been a significant increase in SCI during the last decade as consequence of falls, probably 
due to aging of the population (https://www.nscisc.uab.edu/reports.aspx). There is also a 
progressive increase of traumatic spinal cord diseases among older adults from 79.4 per 
million in 2007 to 87.7 by the end of 2009 (Selvarajah et al. 2013). For studying traumatic 
SCI injuries in the last years a lot of animal models were developed and used. For SCI 
research, it is essential to establish an ideal animal model of injury. Ideal models should 
meet the following conditions (Akhtar, et al. 2008): (1) simulate damage that is similar to 
clinical SCI; (2) control over conditions, reproducibility, stability; (3) involve a simple 
technique that is easy to study; (4) the equipment used to make a model is straightforward 
and quick to produce. All these principles are still valid for other types of models such as in 
vitro models. Differences in injury exist between experimental and clinical SCI. In both 
experimental and clinical SCI, contusion and compression are two of the most common 
injury types. However, in experimental animals, these injuries are frequently induced 
dorsally and in the thoracic spine, whereas most clinical injuries occur anteriorly and in the 
cervical region (Akhtar et al. 2008). According to the National Spinal Cord Injury Statistical 
Center, in 2005, 51% of SCI cases in the U.S. occurred in the cervical region (Akhtar et al. 
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2008). Most SCI in humans affects the anterior spinal artery that supplies three quarters of 
cord tissue, in contrast to the dorsal arteries affected in experimental SCI (de la Torre 1981). 
  
 
Figure 1.1. Modified from NSCISC 2014 Facts 
 
1.2.3 Non-traumatic SCI 
In parallel with a general decrease in the incidence of trauma-related SCI, another trend has 
been observed, namely that non-traumatic SCI cases are increasing in percentage of the 
total SCI affected persons reaching a total amount to 30-50% of spinal cord disorders (Nair 
et al. 2005). Non-traumatic SCI can constitute a very important risk factor during 
rehabilitation from thrombosis, spasticity or wound infections (McKinley et al. 2002) because 
it may be caused by non-traumatic events due to vertebral stenosis, tumors, vascular 
ischemia, inflammatory conditions or subsequent to abdominal aorta surgery ( Van den Berg 
et al. 2010; Bianchetti et al. 2013; Nair et al. 2005). In general, non-traumatic lesions are 
incomplete with severe clinical symptoms including paralysis and sensory dysfunction (Van 
den Berg et al. 2010; Nair et al. 2005). Tumor compression, tissue degeneration or vascular 
problems that can occur during aging increase the risk of non-traumatic SCI in elderly people 
in contrast to traumatic SCI that is less common during the late phase of life (Van Den Berg 
et al. 2010). Recently our lab developed an in vitro model of damage using a particular type 
of pathological medium and keeping isolated newborn spinal cord in vitro for 24 hours (G. 
Taccola et al. 2008), mimicking post-ischemia like environment. We also further analyzed 
the role of magnesium in this particular medium (Bianchetti et al. 2013) unrevelling the role 
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of this ionic imbalance in ischemic conditions characterized by low oxygen level (Bianchetti 
et al. 2013; Margaryan et al. 2009; Taccola et al. 2008).  
 
1.3 PHASES OF SCI 
 
Understanding the pathophysiological processes occurring after acute SCI is the first step 
for developing new neuroprotective strategies based on a pharmacology approach. No 
matter of its origin, all the different types of traumatic and non traumatic SCI follow similar 
pathways of evolution (Figure 1.2) that has been divided in three main phases: the acute 
and immediate (or primary), the secondary and the chronic injury processes (Hulsebosch 
2002; Tator 1995). 
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Figure 1.2: Pathophysiology of the postlesional secondary damage. A spinal cord injury expands itself during 
the first weeks posttrauma due to both (A) systemic and (B,I–V) local effects (modified from Tator, 1995). The 
cascade of secondary damage is presented in the flow diagram within the schematic neuron. (C) The 
timeprogression after spinal cord injury: upon the start of the undirected depolarization (loss of membrane 
integrity) glutamate is released (astrocytes, neurons), this causesthe activation of the neighboring neurons 
(metabolic stress) and moreover the continuation of the formation of free radicals (Schwab et al. 2006). 
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1.3.1 The Immediate or primary injury phase (1-2 h) 
The first events of traumatic SCI are compressive-contusive-type injuries due to fracture or 
dislocation of the spinal column and include shearing, laceration, and/or acute stretching. 
After this mechanical damage, over a matter of a few minutes, the injured neurons respond 
with abnormal firing of action potentials and significant electrolytic unbalance of the levels 
of Na+, Ca2+, K+. Whenever this condition persists for up to 24 hours, spinal cord networks 
become severely damaged (Hulsebosch 2002; Rowland et al. 2008). In parallel with this 
networks impairment, other events occur like parenchymal hemorrhages in the white and 
grey matter (Kakulas 2004; Quencer et al. 1986). During this initial process there is also an 
upregulation of proinflammatory cytokines TNFα and IL-β and activation of microglia 
(Marcello et al. 2013; Pineau and Lacroix 2007). During the following 24 hours, the 
depolarization induces a massive release of neurotransmitters, including glutamate that is 
involved in excitotoxicity (Lipton and Rosenberg 1994); this can be one step in the disease 
process when decreasing the concentration of excitotoxic compounds may limit or arrest the 
extension of the damage (Norenberg et al. 2004). 
 
1.3.2 The Secondary injury phase (2h to 2 weeks) 
The main actors in secondary injury phase are cell death due to ischemia, the electrolytic 
shift and the edema from the acute primary phase. The whole event is subdivided in two 
further moments, the early acute and the sub-acute stage (Hulsebosch 2002; Rowland et 
al. 2008). Within the first two hours, the increase in extracellular concentration of glutamate 
and other excitatory amino acids such as aspartate causes high level of neuronal deaths via 
activation of multiple pathways. Thus, this is another timepoint when pharmacology 
treatments targeting the general biochemical damage can help to constrain the amplification 
of the lesion (Hulsebosch 2002; Kakulas 2004; Lipton and Rosenberg 1994; Rowland et al. 
2008; Tator and Koyanagi 1997). During the subacute stage, that continues for two weeks 
after the injury, there is a delayed astrocytic response: the periphery of the lesion becomes 
hypertrophic and proliferative with a strong increase in glial fibrillary acid protein expression. 
The lesion grows in size from the initial core of cell death with cells at risk of dying in the 
periphery of the lesion site (Herrmann et al. 2008; Hulsebosch 2002; Pineau and Lacroix 
2007). 
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1.3.3 Glial Scar formation and Chronic phase (>6 months) 
After the secondary injury phase, the delayed astrocytic response leads to the formation of 
a scar that block any possible regenerative axonal sprouting, which is, therefore, insufficient 
for recovery from severe SCI (Hill et al. 2001) (Figure 1.3 for examples). The beginning of 
the scar formation consists of Wallerian anterograde degeneration of axons, and 
demyelination near the lesion site (Norenberg et al. 2004). Subsequently, the astroglial scar 
replaces the destroyed myelinated axons, while opposing neurite outgrowth (Bovolenta et 
al. 1993; Norenberg et al. 2004). The final stage is the so-called myelomalacia, a 
pathological condition of softening of the spinal cord with potential evolution into the 
formation of intramedullary cysts. 
 
 
Figure 1.3: Contusion of the spinal cord subsequent to a luxation fracture of the spinal column. (A) Frozen 
section. Patient died acute of another cause (with kind permission of Dr. v. Rauschning). (B) 35 years old 
patient with an acute fracture/luxation at T12/L1, contusion of the spinal cord leading to complete paraplegia 
after a car accident. (C) Repositioning and stabilization of the fracture on the day of the accident after 
laminectomy using an internal fixation and full persistence of the complete paraplegia. (D) 14 days after an 
overhemisection-transection injury: a mature scar in an experimental model is clearly detectable (arrows). The 
scar is, besides myelin, an important barrier for the regeneration of sprouting axons. (From Schwab et al. 2006) 
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1.4 EXCITOTOXICITY AS A MOLECULAR MECHANISM UNDERLYING 
SECONDARY DAMAGE AFTER SCI 
 
Death of CNS neurons during acute injury occurs as a result of a complex combination of 
excitotoxicity, necrosis, apoptosis, edema and inflammatory reactions (Aarts and Tymianski 
2004). One process contributing to the propagation of delayed cell death after an acute SCI 
is excitotoxicity. There is a strong correlation between the loss of ionic homeostasis and 
excitotoxicity during the acute phase of SCI. Excitotoxicity is a process of overactivation of 
excitatory amino acid receptors causing neuronal cell death (Park et al. 2004; Szydlowska 
and Tymianski 2010). The principal excitatory neurotransmitter in the central nervous 
system (CNS) is glutamate released from vesicles in the presynaptic terminals into the 
synaptic cleft. Excitotoxicity involves glutamate postsynaptic receptors, in particular 
ionotropic receptors such those sensitive to NMDA, AMPA or kainate (Aarts and Tymianski 
2003; Kumar et al. 1991) and other Ca2+ permeable receptors such as TRPM family (Aarts 
and Tymianski 2003; Kaneko et al. 2006; Schmitz and Perraud 2005). Ionotropic receptors 
activation increases Na+, K+ and Ca2+ permeability causing an overload in the network 
activity of the system and an imbalance in Ca2+ compartmentalization triggering cell death 
pathways relying on calcium-dependent enzymes. (Szydlowska and Tymianski 2010). 
Tymianski et al. (1993) suggested that Ca2+ influx via NMDA channels is more toxic than the 
one entering via other sources, proposing a sort of “source specificity” (Arundine and 
Tymianski 2003; Mattson 2000). The imbalance in calcium homeostasis can also occur due 
to its release from the endoplasmic reticulum or mitochondria due to physical damage during 
acute injury. The increase of cytoplasmic calcium concentration can trigger downstream 
neurotoxic cascades including inhibition in energy supply from ATP and activation of 
enzymes such as proteases, protein kinases, nitric oxide synthase (NOS), calcineurin and 
endonucleases (Mattson 2000; Szydlowska and Tymianski 2010). All this metabolic stress 
contributes to glutamate-induced neuronal death occurring during the secondary damage 
phase (Thayer and Wang 1995). Drugs designed to block the entry of calcium into neurons 
have failed to produce a positive outcome in clinical trials, as these treatments often elicited 
side effects such as reduced level of consciousness, hallucinations, hypertension and, in 
the worst cases, death (Davis et al. 2000; Lee et al. 2000; Szydlowska and Tymianski 2010).  
Motoneurons are a quite fragile type of cell due to the low levels of glutamate necessary for 
their activation, and this fragility expose this type of cell to the damaging effects elicited by 
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high glutamate concentration. AMPA receptors on motoneurons often lack the GluR2 
subunit rendering them more permeable to Ca2+ (Van Damme et al. 2002). Furthermore, 
Ca2+ binding proteins (e.g. parvalbumin and calbindin) are poorly expressed in the majority 
of motor neurons limiting their calcium buffering capacity (Ince et al. 1993). Excitotoxicity 
affects glial cells too, in which the increase in extracellular glutamate concentration leads to 
a late-response with microglia activation and release of pro-apoptotic factors (Araque et al. 
2000), and a decrease in the activity of transporters (Li and Stys 2001). Excitotoxicity is not 
only involved in SCI, but it is also proposed to underlie a variety of neurological diseases 
such as stroke, traumatic brain injury, multiple sclerosis, Alzheimer’s disease, amyotrophic 
lateral sclerosis (ALS), Parkinson’s disease, and Huntington’s disease (Singleton and 
Povlishock 2004). 
 
1.5 NEUROPROTECTION IN SPINAL CORD 
 
1.5.1 Exogenous compounds for neuroprotection 
Although advances in pharmacotherapy for the purpose of limiting neuronal injury and 
promoting regeneration after spinal cord injury (SCI) have been achieved, only 
methylprednisolone (MP), administered within the first few hours at high concentration, is 
used in accordance with USA guidelines (Peter Vellman et al. 2003). MP, which attenuates 
the peroxidation of membrane lipids and post-traumatic inflammation, has been reported to  
improve neurobehavioural outcomes in preclinical studies (Braughler and Hall 1984). The 
administration of MP, however, is not without important side effects; therefore, its use in 
treating SCI is controversial (Nash et al. 2002; Shen et al. 2005). Another drug is interleukin 
10 (IL-10) that allegedly shows therapeutic potential related to its trophic effects on spinal 
cord neurons, downregulation of the apoptotic factors Bax and caspase 3, and upregulation 
of anti-apoptotic factors Bcl-2 and Bcl-xl, and neuroprotection against excitotoxicity through 
the PI3K-AKT pathway. Although it is unlikely that IL-10 alone would improve the condition 
of an acute SCI patient, its use in conjunction with other treatment models could potentially 
be valuable, since treatment may necessitate manipulation of spinal cord tissue, leading to 
harmful secondary inflammation. Nonetheless, published data on IL-10 use in a chronic SCI 
model are few and discontinued at the present time (Thompson et al. 2013). Recently 
another compound, namely erythropoietin (EPO) has been described as a glia- and neuro-
protective drug (Goldman and Nedergaard 2002; Gorio et al. 2002). In addition to its anti-
inflammatory role (Agnello et al. 2002), EPO is claimed to possess protective characteristics, 
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e.g., through activation of the anti-apoptotic Janus-kinase-2 pathway. Furthermore, it 
allegedly normalizes the autoregulation of vessel tone and suppresses the release of nitric 
oxide. Unfortunately, by interfering with blood flow, EPO causes an augmented haematocrit 
value and an increased aggregation of thrombocytes (Erbayraktar et al. 2003; Schwab et al. 
2006).  
While other compounds have been studied before such as anaesthetic agents (including 
Xenon gas, with anti-excitotoxic properties), ormones such as 17-estradiol, progesterone, 
thyrotropin-releasing hormone (TRH) and its analogues, clinical trials with these substances 
are few and with frustrating results (Onose et al. 2009).  
More recently our lab has focused on the role of other pharmacological compounds, such 
as riluzole or methoxyflurane, showing neuroprotection effects against excitotoxicity in an in 
vitro model using kainate as a glutamate analogue for eliciting excitotoxic damage (Mazzone 
and Nistri 2011; Shabbir et al. 2015). Both these compounds act during the first phases of 
secondary injury damage by preserving components of the neuronal network activity and by 
preventing excitotoxicity within a short timeframe. Unfortunately it has been reported that 
methoxyflurane administered for long time to man can release fluoride with toxic effects on 
peripheral organs like the kidney (E D Kharasch et al. 1995; E D Kharasch et al. 2006). 
Although with fewer side effects, riluzole seems to provide incomplete neuroprotection to 
the spinal cord network after injury (G L Mazzone and Nistri 2011). Other strategies and 
combined application of several agents seem to be necessary: future studies should address 
this issue. 
 
1.5.2 Pharmacology and neuroprotection 
Activated microglia releases glutamate and neurotoxic pro-inflammatory molecules such as 
cytokines and cytotoxic factors, thus amplifying excitotoxic damage and exacerbating 
neurodegeneration (Barger and Basile 2001; Barger et al. 2007; Cunningham et al. 2005; 
Parker et al. 2002). In addition, prolonged activation of microglia will prevent these cells from 
carrying out their supportive role to neurons such as release of growth factors (Benoit et al. 
2008). Blocking microglial activation has been demonstrated to be neuroprotective in a 
mouse model of Parkinson’s disease (Wu et al. 2002). In general altering microglial 
activation in neurodegenerative processes is likely to have multiple beneficial consequences 
on the progression of pathologies (Williams and Dexter 2014). Different models of SCI have 
indicated that glutamate receptor antagonists may be useful therapeutic strategies in terms 
of improved behavioural outcome and neuroprotection (Hulsebosch 2002). The 
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noncompetitive NMDA ion channel blocker MK-801 (dizocilpine, Merck) and NBQX, a 
soluble AMPA receptor antagonist, have both demonstrated significant improvements in the 
contusion model of SCI in outcome measures of improved behaviour and neuroprotection 
(Faden and Simon 1988; Gorgulu et al. 2000; Li and Stys 2001; Nesic et al. 2001; Wada 
and Shikaki 1999; Wrathall et al. 1996). In the case of NBQX, the neuroprotection occurs 
principally in the oligodendrocyte population (Rosenberg, Teng, and Wrathall 1999). Other 
studies showed that the NMDA antagonists gacyclidine and agmantine, which inhibits nitric 
oxide synthase too, have demonstrated neuroprotective effects (Yu et al. 2000). Recently 
the group I metabotropic glutamate antagonists showed neuroprotective effects on a model 
of contusion SCI (Mills et al. 2002). 
  
1.6 SPINAL CORD METABOTROPIC GLUTAMATE RECEPTORS  
 
After injury there is a short window characterized by large amount of glutamate release at 
the injury site (McAdoo et al., 1999). This event leads to the activation of glutamate 
receptors, which are divided into two major types: ionotropic receptors (iGluRs) further 
divided into 3 groups, NMDA, AMPA and KA receptors; and metabotropic receptors 
(mGluRs).  
The mGluRs are divided in three groups based on sequence homology (table 1), 
transduction mechanism and pharmacology. Group I mGluRs (mGluR1/5) stimulate 
phospholipase  C (PLC), activate protein kinase C (PKC), and increase Ca2+ release from 
internal storage sites. Both group II (mGluR2/3) and group III (mGluR 4/6-8) are coupled to 
inhibition of adenylyl cyclase. All the mGluRs are G-protein coupled and their activation 
affects multiple intracellular signalling pathways having long-lasting effects (Mills et al., 
2002). 
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Table 1.1 
This table lists different families of mGluRs, their main effects, and their agonist and antagonist and their 
location in the synaptic cleft (Niswender and Conn 2010). 
 
The laminar distribution of mGluRs in the dorsal horn is well characterized (Alvarez et al. 
2000; Jia et al. 1999; C D Mills et al. 2001). mGluR1 is found primarily in deeper laminae 
(III-V), whereas mGluR5 is found in all laminae of the dorsal horn (I-V), but mainly in lamina 
II. Localization of mGluR2/3 is found predominately in II, with decreasing expression through 
laminae III and IV.  
In the CNS, group I mGluRs are found at both presynaptic and postsynaptic sites and their 
activation can increase transmitter release (J. P. Pin and Bockaert 1995). Group II and III 
instead are primarily presynaptic (Liu et al. 1998; Lujan et al. 1996; Neki et al. 1996; Ohishi 
et al. 1995; Petralia et al. 1996; Shigemoto et al. 1997) and can inhibit neurotransmission 
(Baskys and Malenka 1991; Forsythe and Clements 1990; Gereau and Conn 1995; Macek 
et al. 1996; Trombley and Westbrook 1992; Vignes et al. 1995) (Figure 1.4).  
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Figure 1.4. Schematic overview of mGluRs at the synapse. In general, group I (green) are localized 
postsynaptically, and group II (blue) and III (red) receptors are localized in presynaptic locations, (Figure 
modified from Niswender and Conn, 2010) 
 
A large amount of work has demonstrated that mGluRs are key components in nociceptive 
processing. Activation of spinal group II mGluRs leads to depression of neuronal hyper-
responsiveness following inflammation (Stanfa and Dickenson 1998) and reduces 
nociceptive behaviour to noxious mechanical stimuli (Dolan and Nolan 2000). Activation of 
spinal group III mGluRs decrease nociceptive responses and reverse central sensitization 
(Fisher and Coderre 1996; Neugebauer et al. 2000). Furthermore, activation of group II and 
III mGluRs may confer neuroprotection by reducing Ca2+ influx through voltage-dependent 
Ca2+ channels (Gerber et al. 2000; J.-P. P. Pin and Duvoisin 1995; Takahashi et al. 1996). 
The typical orthosteric agonist of group III mGluRs is L-AP4, which is highly selective for 
group III mGluRs relative to other mGluRs or ionotropic glutamate receptors (Schoepp et al. 
1999). L-AP4 has submicromolar to low micromolar potencies at mGluRs 4, 6 and 8, but 
submillimolar to millimolar potency at mGluR7 (Schoepp et al. 1999). Each of the group III 
mGluRs has been genetically deleted in mice, who display several interesting phenotypes. 
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Of the groups related to the spinal cord mGluRs 4, 7 and 8, it is known that mGluR4 is 
predominantly presynaptic (Corti et al. 2002) as mice lacking this receptor show impairment 
in cerebellar synaptic plasticity and in learning certain complex motor tasks (Pekhletski et 
al. 1996). These animals also show impaired abilities in spatial memory performance (Gerlai 
et al. 1998). mGluR4 has also been shown to modulate GABA(A) receptor-mediate seizure 
activity (Snead et al. 2000), and mGluR4-/- mice lack motor stimulatory effects induced by 
ethanol (Blednov et al. 2004). mGluR7 exhibits a wide distribution throughout the entire 
brain, has low affinity for glutamate and is highly localized to active zones of synapses 
(Kinoshita et al. 1998; Shigemoto et al. 1997). In previous studies it has been proposed that 
mGluR7 operates like a low pass filter during neurotransmission acting as a brake for 
overstimulation, as it becomes active only when the glutamate concentration becomes too 
high (Niswender and Conn 2010). Supporting this hypothesis, mGluR7 knockout mice are 
prone to manifest seizure and epilepsy, and also have problems in learning (Sansig et al. 
2001). mGluR7 function appears to be very important in mediating learning dependent on 
amygdala activation: moreover, these mice display disorders such as anxiety and 
depression (both related to amygdala and limbic system) (Callaerts-Vegh et al. 2006; 
Masugi et al. 1999). Finally, mGluR8 is expressed at lower levels than mGluR4 and mGluR7, 
but it has wide distribution throughout the CNS. It is localized predominantly presynaptically, 
although it has been identified at some post-synaptic locations and in the periphery 
(Lavreysen and Dautzenberg 2008). The mGLuR8 gene is large, spanning exceptionally 
1000 kilobases of genomic DNA in the same region. Mutations cause two human disorders, 
i.e. the Smith-Lemli-Optiz syndrome and retinis pigmentosa (Scherer et al. 1997). mGLUR8 
knockout mice show enhanced anxiety and weight gain compared to controls, suggesting a 
role for mGluR8 in controlling anxiety disorders and network excitability (Linden et al. 2002).  
  
1.7 ADENOSINE RECEPTORS IN SPINAL CORD 
 
Adenosine (ADO) has been shown to be involved in multiple pathological processes like 
pain, stroke, spinal cord injury and Parkinson’s disease (Dunwiddie and Masino 2001; 
Fredholm et al. 2011; Greene and Haas 1991; Latini and Pedata 2008; Lopes et al. 2011; 
Paterniti et al. 2011; Sperlágh and Vizi 2011). Former studies demonstrate that ADO 
activates A1, A2A, A2B, and A3 receptor and that inhibition mediated by A1 receptors is the 
most common and until now the well-known action on neurons in different brain areas 
(Porkka-Heiskanen and Kalinchuk 2011; Schmitt et al. 2012). ADO roles are currently 
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investigated in neuron-glia interactions during sleep deprivation (Porkka-Heiskanen and 
Kalinchuk, 2011; Schmitt et al., 2012). The latter studies and the above reports state that 
extracellular ADO rises in proximity of excited neurons to modulate their activity. Mutual 
interactions between ADO and neuronal activities have been studied thoroughly for the 
spinal central pattern generator (CPG) controlling swimming movements in tadpoles ( Brown 
and Dale 2000; Brown and Dale 2002; Dale and Gilday 1996; Dale 1998). In this system, 
rhythmic CPG activity leads to release of ATP into spinal cord networks where it is then 
degraded enzymatically to ADO which subsequently terminates bouts of swimming. The 
blocking effect by 8-phenyltheophylline on this ADO action suggests an involvement of A1 
receptors (Dale and Gilday 1996). Focal injection of ATP into newborn mouse brainstem 
slices does not accelerate pre-Bӧtzinger complex (preBӧtC) inspiratory bursting that is 
normally mediated by P2 receptors because of the rapid degradation of this typically 
excitatory neuromodulator to ADO that activates A1 receptors (Zwicker et al. 2011). 
Furthermore, a modest slowing of inspiratory-related rhythm is seen upon ADO injection into 
the mouse preBӧtC slices (Ruangkittisakul and Ballanyi 2010). All these results suggest that 
the inspiratory CPG in the newborn rat is insensitive to ADO in contrast to its slight 
depressing effects on the mouse preBӧtC. As a further example for species differences of 
ADO effects on CPGs, ADO blocks bursting in rat cervical cord networks caused by inhibition 
of GABAA receptors or glycine receptors (Brockhaus and Ballanyi 2000), but it does not 
affect the “disinhibited” rhythm in the mouse lumbar cord (Witts, Panetta, and Miles 2012). 
 
1.8 SPINAL CORD MODEL IN VITRO 
 
In addition to in vivo animal models of SCI (Onifer et al. 2007), there have been numerous 
reports to develop new in vitro models that can lead to useful data and discoveries, and to 
understand mechanisms of SCI pathophysiology. Examples of in vitro models are cell 
cultures, organotypic cultures or isolated spinal cord preparations. In vitro models have 
certain important advantages, for example simplification of the complexity of in vivo 
pathophysiology allows studying certain processes without interference from blood pressure 
or anesthesia. Primary cultures from spinal cord tissue have been studied for reproducing 
in vitro excitotoxicity (Van Den Bosch et al. 2000; Taylor et al. 2007) and secondary damage 
due to lack of oxygen (Kaushal and Schlichter 2008). Despite these advantages, these 
culture models present many disadvantages like the presence of artificial culturing media, 
random assembly of synaptic contacts, and lack of endogenous substances that may be 
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fundamental for axon growth and regeneration (Abu-Rub et al. 2010; Silani et al. 2000). 
Other models are based on organotypic spinal cultures (Guzman-Lenis, Navarro, and Casas 
2009), in vitro spinal slices (Zhang et al. 2010) and even an incision model (Que et al. 2011). 
The principal advantage of the organotypic model is the preservation of the basic 
cytoarchitecture of the tissue with the dorsal/ventral orientation of the spinal segments. 
Furthermore, this model enables long-term studies stretching over weeks during which 
changes in network properties can be explored in relation to changes in the local 
environment (Sibilla and Ballerini 2009). However, these cultures cannot generate 
locomotor rhythms that require a minimum of three intact spinal segments with undamaged 
connections. The same limitation applies to acute slices of the spinal cord that can be used 
for performing functional studies and network pharmacology, though lacking the locomotor 
circuits.  
 
1.8.1 Neonatal rat isolated spinal cord preparation 
Our group has recently developed a novel model of in vitro SCI, in order to investigate the 
rapid events during early secondary damage (G L Mazzone et al. 2010; G. Taccola et al. 
2008). It is a model based on the neonatal rat isolated spinal cord, in which we can mimic 
both non traumatic and incomplete SCI (Kuzhandaivel et al. 2010; Kuzhandaivel et al. 2010; 
Taccola et al. 2008; Taccola et al. 2010) with the aim of mimicking, under experimental 
conditions, the acute clinical setting occurring in vivo. When applying kainic acid for one 
hour, excitotoxic damage is evoked due to large release of endogenous glutamate plus 
direct activation of glutamate receptors by this agonist. After this application, the solution 
containing kainate is washed out using standard Kreb’s solution for 24 hours. Although this 
model lacks the immune system responses and vascular supply, it permits monitoring over 
a period of 24 hours after the kainic acid treatment, the functional responses of the neuronal 
networks and the number, type and topography of damaged or dead cells. This type of 
preparation also shows a type of locomotor-like activity (termed fictive locomotion) that can 
be used as a biomarker for correct performance of the spinal cord networks. This is a very 
important point due to the relationship between the extent of loss of electrophysiological 
function and the extent of damage (Mladinic and Nistri 2013; Nistri et al. 2010).  
 
1.8.2 Organotypic slices from rat embryos  
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Another model recently developed in our laboratory for testing excitotoxicity induced by the 
glutamate agonist kainate is the organotypic spinal culture that mimics the early pathological 
processes occurring during the secondary damage caused by kainic acid (Mazzone et al., 
2010). With this model, kainate toxicity is primarily directed to neurons rather than glia, and 
it develops slowly through the hyperactivation of the intracellular enzyme poly(ADP)ribose 
polymerase-1 (PARP-1) that triggers cell energy failure and DNA damage ( a Kuzhandaivel 
et al. 2010; Graciela L Mazzone and Nistri 2011a; Nasrabady et al. 2011). Our laboratory 
has evaluated the effects of riluzole on the excitotoxic glutamate release, the release of 
lactate dehydrogenase (LDH) (used as a marker of cell damage; Hori et al. 2001), metabolic 
activity of organotypic cultures (with the MTT test; (G L Mazzone et al. 2010)), and number 
of surviving neurons. 
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CHAPTER 2: AIMS OF THE STUDY 
 
2.1 Role of mGluR III Group in Excitotoxic Neuroprotection 
Our previous studies demonstrated that in the rat isolated spinal cord or organotypic 
cultures, kainate induces a large neuronal depolarization followed by neuronal death (G L 
Mazzone et al. 2010; Graciela L Mazzone and Nistri 2011a; G. Taccola et al. 2008). The 
depolarizing action of kainate is associated with a strong release of endogenous glutamate 
that peaks in less than 25 minutes in Ca2+ free medium(G L Mazzone and Nistri 2011b). The 
present study follows similar protocols (G L Mazzone and Nistri 2011; Shabbir et al. 2015)  
to investigate the role of L-AP4, a mGluR III group agonist (Thomsen 1997), in modulating 
the effects of excitotoxicity induced by kainate on organotypic spinal cord cultures. Group III 
metabotropic glutamate receptors (mGluR III) are known to decrease glutamate release and 
to play an important role in controlling pain as documented in neuropathic pain models. 
Much less is known about their potential neuroprotective effect against excitotoxicity that is 
considered important for damage onset of spinal cord injury (Pizzi et al. 2000). Using the rat 
spinal cord organotypic slices model, we wished to investigate if mGluR III receptor 
activation might contrast excitotoxic cell death evoked by kainic acid (0.1 mM). Furthermore, 
for better understanding the events that occur during excitotoxicity and L-AP4 effects, we 
applied CPPG, an mGluR III group antagonist (Niswender and Conn 2010) to find out if 
block of endogenous activation of mGluR III group by glutamate release leads to an increase 
of excitotoxic cell death.  
2.2 Characterization and developing of a 3 days in vitro isolated spinal 
cord. 
Increasing the survival of the rat spinal cord in vitro for more than 1 day is a very interesting 
challenge. Obtaining this type of new model can lead to the discovery of new information 
related to the late-onset events that occur in the SCI. Thus, we wished to try to keep an 
isolated neonatal rat spinal cord in vitro for at least 3 days after the laminectomy. For 
understanding if the spinal cord in vitro is an effective model, we evaluated the extent of cell 
death after the 3 days and the electrophysiological properties such as the ability to generate 
fictive locomotion (Taccola et al., 2008) elicited by NMDA and serotonin (5-HT).  
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Animal Procedures 
 
3.1.1 Organotypic Slice of rat embryonal spinal cord 
Pregnant Wistar rats, at day 13 of gestation, were used for producing embryonic organotypic 
slice cultures of spinal cord in accordance with previously published procedures (Avossa et 
al. 2003; L Ballerini et al. 1999; Laura Ballerini and Galante 1998; Gähwiler and Capogna 
1997; G L Mazzone and Nistri 2011; G L Mazzone et al. 2010). The fetuses were delivered 
by caeserean section from anaesthetized rats (10,5% chloral hydrate, 0,4 ml/100 g i.m.) 
subsequently killed by an intracardiac injection (2 ml) of chloral hydrate. This procedure is 
in accordance with the regulation of Italian Animal Welfare Act and is in accordance with the 
National Institute of Health (NIH) guidelines. Fetuses were decapitated and their backs, 
isolated form their limbs and viscera, were cut into 275 µm thick transverse slices from which 
the spinal cord was punched out and fixed on a glass coverslip with reconstituted chicken 
plasma coagulated by one drop of thrombin (200 U/ml). Coverslip were inserted into plastic 
tubes with 1 ml of medium contained 82% Dulbecco’s Modified Eagle’s Medium, 8% sterile 
water for tissue culture, 10% fetal bovine serum (FBS; Invitrogen, Italy), osmolarity 300 
mOsm, pH 7.35. For each dissection, 30-40 slices were prepared from thoracic as well as 
the lumbar segments, and kept in culture for 22 days in vitro (DIV) before use. The tubes 
were kept in a roller drum rotating (120xg/h) at 36.5 °C. Dulbecco’s Modified Eagle’s medium 
with high glucose (DME/HIGH), penicillin, and streptomycin (purchased from Euroclone, 
Devon, UK). Fetal calf serum was obtained from Invitrogen, (Carlsbad, CA, USA). Nerve 
growth factor (NGF) was from Alomone Laboratories (Jerusalem, Israel), chicken plasma 
from Rockland (Gilbertsville, PA, Usa), and thrombin from Merck, (Darmstadt, Germany).  
 
3.1.2 Newborn rat spinal cord preparation 
In accordance with the NIH guidelines and Italian act Decreto Legislativo 27/01/1992 n.116 
(implementing the European Community directives n.86/609 and 93/88), 0-2 day old Wistar 
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rats were anesthetized with urethane. All efforts were aimed at reducing the number of 
animals used for the present project and at minimizing their suffering. Subsequently, the 
spinal cord was isolated by laminectomy in Kreb’s solution containing (in mM): 113 NaCl, 
4.5 KCl, 1 MgCl2·7H2O, 2 CaCl2, 1 NaH2PO4, 25 NaHCO3, 11 D-glucose. The solution was 
gassed with 95% O2-5% CO2 to establish a pH of 7.4 at room temperature. For 
electrophysiological recording, one spinal cord was positioned in an acrylic chamber with a 
volume of 5 ml that was perfused with Kreb’s solution at a flow rate of 5 or 7.5 ml/min. All 
details about laboratory procedures have been previously published (M Beato et al. 1999; 
Beato et al. 1997; Bracci et al. 1996a, 1996b) and the experimental setup has been fully 
reported (Margaryan et al. 2009; G. Taccola et al. 2008; Taccola and Nistri 2006). Drugs 
were dissolved in Krebs solution and bath applied at the concentration indicated in the text. 
 
3.1.3 Newborn Isolated 3 days in vitro spinal cord 
After isolation, the neonatal spinal cord was put in a 50 ml tube with 20 ml of Basal Medium 
(Life Technologies), Nerve Growth Factor 7S 30mg/ml (Sigma Aldrich), Insulin 10 µg/ml 
(Sigma Aldrich), Amphotericin B (Fungizone) 250mg/ml (Sigma Aldrich), Gentamycin 100 
µg/ml (Sigma Aldrich). The medium was oxygenated and keep sterile for all the 3 days.  
 
3.2 Staining and Immunohystochemistry procedures 
3.2.1 Immunofluorescence of organotypic slices cultures 
Slices were fixed in 4% paraformaldehyde for 1 hour at room temperature and stored in 
phosphate buffer saline (PBS) until use. Cultures were processed for immunofluorescence 
analysis by immersion for 10 minutes in trypsin solution (0.05% in sterile water) at 37°C. 
Slices were then blocked with 3% fetal calf serum (FCS), 3% bovine serum albumin (BSA), 
0,3% Triton in PBS (blocking solution) for 1 hour at room temperature, followed by overnight 
incubation at 4°C in a blocking solution containing the antibodies. The following antibodies 
were employed: NeuN antibody (Millipore) at 1:500 dilution; SMI 32 antibody at 1:1000 
dilution, mGluR4 (Santa Cruz Biotech), mGluR7 (Novus Biologicals), mGluR8 (Millipore) at 
1:1000 dilution. The primary antibody was visualized using corresponding secondary 
fluorescent antibody (Alexa Fluor 488, at 1:500 dilution, Invitrogen, Carlsbad, CA, USA). To 
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visualize cell nuclei, slices were incubated in 1 µg/ml solution of DAPI for 20 minutes and 
mounted using DAKO mounting medium (Dako, DK-2600 Glostrup, Denmark).  
 
3.2.2 Quantification of dead cells in organotypic spinal cord cultures 
DAPI staining results were analysed using a Zeiss Axioskop2 microscope. The identification 
and quantification of dead or dying cells in the organotypic cultures was performed as 
previously shown (G. Taccola et al. 2008), using DAPI nuclear staining and “eCELLence” 
software. Three different regions of interest (r.o.i.), namely dorsal, central, and ventral, were 
analysed in each slice (see scheme in figure). The average percent values of nuclei showing 
condensed chromatin (normalized to the total number of nuclei) were compared between 
different r.o.i. for controls or treatments and expressed as mean±SD (using at least three 
different cell culture series for each experimental group).  
 
3.2.3 Quantification of NeuN positive cells in organotypic spinal cord 
cultures 
NeuN positive cells were analysed using a Confocal (Nikon) microscope, equipped with 
Ar/ArKr (at 488 nm) laser whereby a stack of 25-30 images (20x magnification) were counted 
with “eCELLence” software using the same intensity threshold (ranging from 0 to 1 where 1 
refers to the maximum intensity of the image) and cell diameter parameters  for all 
experiments. The total number of NeuN positive cells was obtained for each experimental 
condition as the total number of positive cells in all stacks. Multiple entries of the same object 
were considered as single entities by the “eCELLence” software algorithm. 
 
3.2.4 Quantification of SMI 32 positive cells in Organotypic Spinal Cord 
Cultures 
SMI 32 positive cells were analysed with Zeiss Axioscope Microscopy and “eCELLence” 
software for counting. We evaluate the total number of nuclei positive to SMI 32 
immunostaining in the ventral region of interest near the fissure. 
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3.2.5 Quantification of mGluR signal intensity 
Quantification of Immunofluorescence signals for mGluR 4,7,8 subunits (gray level intensity 
expressed in arbitrary units, AU) was performed with Meta-Vue imagine software (Molecular 
devices, Sunnyvale, CA USA) using the densitometry function to calculate mean signal 
intensity for regions of interest (ventral, central and dorsal) reactive to mGluRs antibodies. 
The values are mean ± SD (at least 9 different cultures with at least one sample from each 
culture).  
 
3.2.6 Fluorescence immunohistochemistry procedure in neonatal 
isolated spinal cord 
The free-floating immunofluorescence protocol was used as previously described (Mladinic 
and Nistri 2013; G. Taccola et al. 2008). The primary antibodies were visualized using 
appropriate secondary fluorescent Alexa Fuor 488 or 594 antibodies (1:500 dilution, 
Invitrogen Carlsbad, CA, USA). Sections were stained in 1 µg/ml solution of 4,6-diaminio-2-
phenylindole (DAPI) for 20 minutes to visualize cell nuclei and mounted on Superfrost Plus 
(Menzel-Glazer, Braunschweig, Germany) slides. The immunostaining signal was analysed 
by Zeiss Axioskop2 microscope (Oberkochen, Germany) using 1µM z sectioning. 
 
3.2.7 Statistical Analysis 
Data were collected from at least three independent experiments, and are expressed as 
mean ± standard error of the mean (SEM), where n indicates the number of independent 
experiments, as indicated in the respective figure legend. Statistical analysis was performed 
using the SigmaStat (SigmaStat 3.1, SystatSoftware, Chicago, IL, USA): after normality test 
values were analysed with one-way ANOVA for multiple comparisons (with Turkey-Kramer 
post-hoc test). For non-parametric values, Kruskal-Wallis one-way analysis of variance and 
the student-Newman-Keuls method test were used for multiple comparison. The accepted 
level of significance was p<0.05. 
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3.3 Electrophysiological recording and stimulation 
Rhytmic motor Central Pattern Generator (CPG) activity was recorded with suction electrode 
form the second and fifth ventral lumbar roots (L2, L5). L2 roots contain axons from 
motoneurons which innervate mainly hindlimb flexor muscles, while L5 roots contain axons 
that drive primarily hindlimb extensor muscles. Locomotor-associated CPG activity 
alternates rostrocaudally between L2 and L5 and bilaterally between ipsilateral and 
contralateral L2 or L5 roots (Clarac et al. 2004; Kiehn 2006; Taccola and Nistri 2006). 
Rhythmic bursting with these characteristics was induced by combined bath application of 
serotonin (5-HT; 10 µM; Sigma-Aldrich, Milan) and N-methyl-D-aspartate (NMDA; 3-5 µM; 
Ascent Scientific, Bristol, UK) and such chemically evoked fictive locomotion was typically 
stable for time period of more than 3 hours (Clarac et al. 2004; Kiehn 2006; G. Taccola et 
al. 2008). Single electrical pulses were applied to dorsal root L5 for eliciting a dorsal 
root/ventral root potential comprising a polysynaptic dorsal root reflex (Marchetti et al. 2001; 
G. Taccola et al. 2008). Tight-fitting suction electrodes filled with control solution were 
applied to the distal cut end of L2 and L5 ventral roots for DC-coupled extracellular 
population recordings via a high input impedance, low noise DC amplifier with a gain of 
x1000. The signals were bandpass-filtered 0.1-10 kHz and fed at sampling rate of 5 kHz via 
an Axon Digital Interface (Molecular Device LLC, Sunnyvale, CA, USA) into a personal 
computer (G Taccola and Nistri 2006). Burst amplitude was calculated at the highest point 
of the activity bout. Values are given in percentage of control because the absolute 
amplitude of extracellular signals depends on various parameters such as suction electrode 
resistance and tightness of the seal between electrode and spinal root. Rhythmic discharges 
were characterized on the basis of their period that is defined as the time between the onset 
of two subsequent cycles of oscillatory activity. For averaging period values from different 
preparations, data from each spinal cord were calculated as the mean of at least 20 burst 
cycles. The regularity of bursting was determined in terms of the coefficient of variation (CV; 
given by the standard deviation [S.D.] mean-1) of the period. Single burst duration was 
calculated between the onset of the event and the start of the rapid phase of its decay. Data 
were quantified as means ± S.D. Parametric data were analysed with t-test, paired t-test for 
two groups, or one way ANOVA followed by a post-hoc analysis for multiple groups. Non 
parametric data were evaluated with Rank Sum test, Signed Rank Sum test for two groups, 
 25 
 
or Kruskal-Wallis one way ANOVA test followed by a post-hoc analysis for multiple groups. 
The accepted level of significance was p<0.05. 
 
3.4 Organotypic Spinal Cord Slices treatments 
As depicted in figure 3.1 the organotypic slices of embryonal spinal cord were subjected to 
different treatments. In the first treatment (Fig. 3.1A) kainate at the concentration of 100 µM 
was applied for 1 hour and L-AP4 at the concentration of 1 µM was either co-applied or 
applied only in the kainate 24 h washout. In the second set of experiments kainate at the 
concentration of 50 µM was applied for 1 hour and L-AP4 and CPPG both at the 
concentration of 1 µM were applied only in the 24 hour washout. In the last set of 
experiments, we applied kainate at the concentration of 100 µM and then L-AP4 1µM and 
adenosine (ADO) at 100 µM either in co-application or during washout only. 
 
Figure 3.1 Different treatments for organotypic spinal cord cultures. The figure illustrates the three different 
types of treatment for evaluating the impact of protection by modulation of mGluR III group receptors and 
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adenosine receptors. Figure 3.1A show the treatment with the application of only L-AP4 after kainate. Figure 
3.1B shows the treatment with application of CPPG or co-application of CPPG and L-AP4 during the kainate 
washout. Figure 3.1C show the coapplication of adenosine (ADO) and L-AP4 during the treatment with kainate 
or during washout. 
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CHAPTER 4: RESULTS 
4.1 Dead cells quantification after kainate 100µM and L-AP4 1µM 
application 
We identified dead cells (using DAPI) characterized by condensed chromatin (example of 
pyknotic nuclei is indicated by black arrow in figure 4.1A). Cell death was quantified in terms 
of percentage of pyknotic nuclei. Percentage of pyknotic nuclei treated with kainate at 
100µM concentration is statistically different (p=0.033) in all the three regions (ventral, 
central and dorsal). L-AP4 co-applied with kainic acid decreased pyknosis from 39±1 to 14±3 
%, and from 16±4 to 2±1 % in the dorsal and ventral regions, respectively, and from 31±3 
to 7±2% in central area. Delayed L-AP4 application was less effective, yet still significant 
with pyknosis decreasing to 32±2% in dorsal, 7±2% in ventral regions and 23±2 % in central 
region (Figure 4.1). There is no deleterious effect using only L-AP4 at 1 µM for 24 hours 
concentration (Figure 4.1C). This results suggests that kainate evokes excitotoxic damage, 
an effect counteracted by the activation of mGluR III group receptors.  
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Figure 4.1 Cell death analysis of organotypic cultures 24 hours after application of kainate in the presence of 
L-AP4 by using the experimental protocol for early excitotoxicity shown in Fig.3.2. (A) Examples of DAPI-
stained cells in the central region in control condition, or after kainate for 1 hour at 100 µM and wash out (w/o) 
with medium, treated with coapplication of kainate 100 µM and L-AP4 1 µM for 1 hour and then washed out 
with medium and L-AP4 or with the application of L-AP4 only in the washout medium. (B) Histograms show 
average percent of pyknotic cells in ventral, central and dorsal region in presence of kainate (100 µM) for 1 
hour with or without L-AP4 (1 µM). In Blue control condition, in red kainate 100 µM only, in green with co-
application of L-AP4 1µM, in purple application of L-AP4 only in the washout (w/o) after 1 hour application of 
kainate. (C) Comparison of example of central region in control condition and treated with L-AP4 for 24 hours.  
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4.2 NeuN positive cells quantification after kainate (100µM) and L-AP4 
1µM application 
To further confirm the action of L-AP4 on kainate induced excitotoxicity, we analyzed the 
NeuN staining (example of central part of organotypic slices in figure 4.2A) counting the total 
number of NeuN positive cells. A statistical increase (p=0.039) in total number of NeuN 
positive residual cells is present in both treatments. For example, in the ventral region from 
193±27 with the application of only kainate at the concentration of 100 µM to 245±34 in the 
co-applied treatment of both kainate 100 µM and L-AP4 1µM. Organotypic slices treated 
with L-AP4 1µM only during kainate wash-out show improved number of NeuN positive cells 
too. In the ventral region, values increase from 193±27 to 238±5 with p=0.041 (Figure 4.2). 
This result shows that the counteracting effect of L-AP4 involves blocking excitotoxic 
damage to neurons. 
 
Figure 4.2 Neuronal loss evoked by kainate 24 hours later can be counteracted by L-AP4. (A) Example of 
central region with NeuN positive neurons 24 hours in complete medium (control), after 1 hour application of 
kainate (100 µM), or kainate and L-AP4 in co-application or only in the washout (w/o) (lower images, 
respectively left and right). (B) Histograms showing average number of NeuN positive cell in the three regions 
analyzed as described above. * P< 0.05 vs kainate (n=8). In Blue control condition, in red kainate 100 µM only, 
in green with co-application of L-AP4 1µM, in purple application of L-AP4 only in the washout after 1 hour 
application of kainate.  
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4.3 SMI 32 positive cells quantification after kainate 100 µM and L-AP4 
application 
We assessed if the group of neuronal cells protected by excitotoxic damage comprise 
motoneurons too. We focus on motoneurons because these are the major group of cells 
that are damaged by excitotoxic events during secondary damage (Van Damme et al. 2002; 
Ince et al. 1993). We use SMI 32 antibody (G L Mazzone and Nistri 2011; G L Mazzone et 
al. 2010; G. Taccola et al. 2008) to identify large diameters (>25 µm) cells in the ventral 
region. Figure 4.3B depicts a strong fall in motoneuron number induced by kainate (100µM) 
with a significant protection by subsequent application of mGluR III group antagonist L-AP4 
either in co-application or only during the washout. The result suggests that mGluR III 
activation is capable of stopping motoneuron death due to excitotoxic damage. 
 
Figure 4.3 Kainate-induced damage of motoneurons in organotypic slice cultures is prevented by L-AP4 
applied even after 1 hour of treatment with kainate. (A) Example of motoneuron staining (with SMI 32 antibody) 
in control, or 24 hours after kainate (100 µM), or kainate co-applied or followed by L-AP4. (B) Histograms show 
number of motoneurons from 8 experiments with 3 slices; * P<0.05 vs control. 
 
4.4 Cell death evaluation after treatment with CPPG, kainate and L-AP4 
Focusing on the neuroprotection effect of L-AP4, we further wished to evaluate the role of 
mGluR III group receptors in excitotoxic events following kainate treatment. For investigating 
these events we used a lower concentration of Kainate (50 µM) to prevent maximum 
damage level at one hour. Previous studies from our laboratory have shown that the release 
of glutamate is slower following 50 µM kainate even if the final damage is as strong as after 
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100 µM (G L Mazzone and Nistri 2011). Figure 4.4 shows that in presence of CPPG during 
the washout after kainate at 50 µM there is more excitotoxic damage compared with the 
damage in kainate alone (e.g. in ventral region: from 9.6±1 to 35±3 %). Co-application of L-
AP4 1 µM with CPPG 1 µM in the washout leads to levels statistically different (p<0.05) from 
both kainate 50 µM and kainate plus CPPG 1 µM treated slices. There is no effect using 
only CPPG at 1 µM for 24 hours in terms of cell death (Figure 4.4C). The result suggests 
that decreasing the activity of mGluR III receptors leads to an increase in glutamate release 
leading to a massive cell death. The co-application of both mGluR III group agonist and 
antagonist decreases the cell death probably due to the different affinity of the two 
compounds with a smaller counteracting effect of L-AP4. 
 
4.5 NeuN positive cells quantification after kainate 50µM and CPPG and 
L-AP4 1µM application 
To better investigate the role of CPPG in kainate induced excitotoxicity, we analyzed the 
NeuN staining (example of central part of organotypic slices in figure 4.2A). A statistical 
decrease (p<0.05) in total number of NeuN positive cells is observed in all regions but not 
incremented by CPPG treatment. For example, in the ventral region from 194±23 with the 
application of kainate at the concentration of 50 µM, treatment with kainate 50 µM and CPPG 
1µM during washout left the same damage (190±34). Organotypic slices treated with L-AP4 
1µM co-applied with CPPG 1µM show an apparent increase in the total number of NeuN 
positive cells without reaching control values (Figure 4.5).  
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Figure 4.4 Characterization of organotypic cultures 24 hours after application of kainate and CPPG. (A) 
Examples of DAPI-stained cells in the central region in control condition, after kainate (50 µM) for 1 hour with 
or without CPPG and co-application with L-AP4, CPPG and KA 50 µM. (B) Histograms show average percent 
of pyknotic cells in ventral, central and dorsal regions in presence of kainate (50 µM) for 1 hour with or without 
CPPG (1 µM) and coapplication of the  three compounds. In Blue control condition, in red Kainate 100 µM 
only, in green with co-application of L-AP4 1µM, in purple application of L-AP4 only in the washout after 1 hour 
application of Kainate. In light blue control condition, in red Kainate 50 µM only, in heavy blue with co-
application of CPPG 1µM, in orange combined application of L-AP4 1µM, Kainate 50 µM and CPPG 1µM. (C) 
example of central region in control condition and with the application of only CPPG for 24 hours.  
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Figure 4.5 Neuronal loss evoked by kainate and CPPG. (A) Example of central region with NeuN positive 
neurons after 24 hours in complete medium (control), after 1 hour application of kainate (50 µM) and CPPG (1 
µM), or kainate, CPG and L-AP4 in co-application during the kainate washout (lower images, respectively left 
and right). (B) Histograms showing average number of NeuN positive cells in the three regions analyzed after 
the protocol described above. * P< 0.05 (n=8). In light blue control condition, in red kainate 50 µM only, in dark 
blue with co-application of CPPG 1µM, in orange application of L-AP4, CPPG  only in the washout phase after 
1 hour application of Kainate.  
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4.6 SMI 32 positive cell quantification after kainate 50 µM and CPPG 
application 
Using the same protocol of SMI 32 antibody staining for identifying motoneurons, we further 
evaluated the impact of CPPG-kainate treatment on these cells. Figure 4.6B depicts a strong 
fall in motoneuron number induced by kainate (50µM) and CPPG (1 µM) in the washout 
similar to the effect by kainate alone. The coapplication of L-AP4 alongside with CPPG in 
the washout phase results in a partial increase in the number of motoneurons without fully 
counteracting the kainate excitotoxic treatment. These data suggest that without fast, strong 
activation of mGluR III group receptors the degree of excitotoxicity is too high for their 
survival. 
 
 
Figure 4.6 CPPG effect on motoneurons. (A) Example of motoneuron staining (with SMI 32 antibody) in control, 
or 24 hours after kainate (50 µM), or kainate followed by CPPG in washout or co-application of CPPG and L-
AP4 during washout. (B) Histograms showing numbers of motoneurons from 8 experiments with 3 slices; * 
P<0.05 vs control. 
 
4.7 Characterization mGluR receptor subunits 
For a better characterization of the events following excitotoxic damage in the spinal cord 
organotypic slices we performed immunostaining against three types of mGluR III group 
subunits that are reported in the spinal cord (Niswender and Conn 2010). We analyzed the 
total intensity of the fluorescence signals of mGluR 4 antibody, mGluR 7 antibody and 
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mGluR 8 antibody to evaluate if there are differences in the localizations of these receptors 
in our model and within the different treatments.  
 
4.7.1 mGluR 8 characterization 
Figure 4.7 shows that the intensity of the signal of the mGluR8 antibody is no different in 
control condition between the three regions of interest. In the organotypic slices treated with 
kainate at 100 µM concentration, there is a decrease in the values of the signal (p<0.01). L-
AP4 co-application counteracts this fall in fluorescence intensity (Figure 4.7C). When slices 
are treated with L-AP4 only during kainate washout, a stronger fluorescence  signal than 
after kainate alone is observed, although this value does not reach the control level.  
 
4.7.2 mGluR 4 characterization 
We next proceeded to characterize the signal intensity of mGluR 4 type subunit. Figure 4.8 
shows that also in this case there is no difference between the three regions of the 
organotypic spinal cord slice. The fluorescence levels after the different treatments appear 
to be broadly comparable with the pattern observed with the mGluR8 one. Notably, there is 
a large decrease of the signal intensity following kainate 100 µM, good preservation with 
kainate and L-AP4 coapplication, and a smaller decrease in the slices treated with L-AP4 
only during the kainate washout. 
 
4.7.3 mGluR 7 characterization 
Finally, the immunohistochemistry signal of mGluR 7 units is comparable with the two 
reported above: thus, there is a strong decrease following kainate 100 µM, a good protection 
level with either co-application of L-AP4 and kainate or delayed application of L-AP4 in the 
three regions of interest.   
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Figure 4.7 Signal Intensity of mGluR8 immunocytochemistry. Panel A shows an example of ventral, central 
and dorsal tissue. There are no differences in immunostaining signal intensity among these three regions. 
Panel B shows an example of the central region of the organotypic slice immunohistochemistry under various 
treatments. C shows histograms depicting the decrease in arbitrary units (A.U.) of the signal between control 
and treatments (**p<0.01, *p<0.05 n=11). w/o=washout of kainate. 
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Figure 4.8 Signal Intensity of mGluR 4 immunohistochemistry. Panel A shows no signal difference among the 
three regions (ventral, central, dorsal, respectively). Panel B shows an example of the central region of  
organotypic slices under various treatments. Panel C shows histograms indicating the decrease in arbitrary 
units (A.U.) of the signal between control and treatments (**p<0.01, *p<0.05 n=9). w/o = washout of kainate. 
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Figure 4.9 Signal Intensity of mGluR 7 immunohistochemistry. Panel A shows is no signal difference among 
the three regions (ventral, central, dorsal, respectively). Panel B shows an example of the central region of the 
organotypic slice immunohistochemistry under various treatments. Panel C shows histograms indicating the 
decrease in arbitrary units (A.U.) of the signal between control and treatments (**p<0.01, *p<0.05 n=11). 
w/o=washout of kainate. 
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4.8 Dead cells quantification after kainate 100µM and L-AP4 1µM and 
adenosine 100 µM application 
My previous work (see attached reprint) has demonstrated that adenosine inhibits the 
excitatory currents recorded from spinal cord neurons. On the basis of these results we used 
adenosine co-applied with L-AP4 to explore a potential increase in cell survival after kainate, 
in particular in central and dorsal regions in which L-AP4 seems to be less effective. We 
applied adenosine at 100 µM concentration together with L-AP4 at 1 µM concentration or 
only during the kainate washout. The preliminary results of nuclear staining with DAPI and 
immunohistochemistry with NeuN and SMI 32 (as done before for the other treatments) 
show no significant improvement in comparison with L-AP4 alone (p>0.05; n=3). 
 
4.9 Spinal Cord 3 days in vitro histology characterization 
To understand if it is viable to keep a neonatal isolated spinal cord in vitro after dissection 
for more than 1 day, we analyzed the newborn rat isolated spinal cord maintained for 3 days 
in vitro. We performed a DAPI staining comparing data with the freshly fixed tissue 
(dissected and fixed) to find out the degree of cell death. Results in Figure 4.10 show no 
difference between the two spinal cord specimens, suggesting that is possible to keep the 
isolated spinal cord in vitro for this length of time. We next analyzed if neurons (labeled with 
NeuN antibody), and motoneurons (labeled with SMI 32 antibody) remain viable after 3 days 
in vitro. The results in panel B and C of Figure 4.10 demonstrate that there is no difference 
in the number of neurons and motoneurons, thus confirming the observations obtained using 
DAPI staining. 
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Figure 4.10 Histological comparison between fresh fixed and 3 days in vitro neonatal isolated spinal cords. (A) 
Example of ventral horn of isolated spinal cord, on the left the fresh fixed tissue, on the right the 3 days in vitro 
spinal cord: the histograms show that there is no difference between the two conditions concerning the 
percentage of pyknotic nuclei in various regions of interest (p>0.05 n=12). (B) Immunohistochemistry results 
for SMI 32 positive cells (motoneurons) showing no statistical difference between the two conditions (p>0.05 
n=12). (C) Immunohistochemistry data for NeuN positive cells (neuronal nuclei) indicating no difference 
between fresh fixed and 3 days in vitro spinal cords (p>0.05 n=12). 
 
4.10 Electrophysiological recording from Spinal Cords kept 3 days in 
vitro  
To support our histological results, we performed electrophysiological recording with NMDA 
(3-5 µM) and 5-HT (10 µM) to elicit fictive locomotion both in P0-P3 fresh isolated neonatal 
spinal cord and in 3 days in vitro isolated spinal cord. In line with histology results as depicted 
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in figure 4.11, there is no statistical difference in the average rhythmicity between the two 
conditions. Analysis of data from 8 spinal cords shows s rhythm with a mean cycle for P0-
P3 freshly isolated preparations of 5.48 ± 0.83 s and a period CV of 0.18±0.04, while for 3 
days in vitro isolated spinal cords a mean cycle of 6.11 ±1.56 s and a period CV of 
0.0.16±0.03 (p>0.05) is present.  
 
Figure 4.11 Fictive locomotion of P3 fresh isolated spinal cord and 3 days in vitro isolated spinal cord. The 
figure shows the absence of significant differences between the two conditions. Two examples of fictive 
locomotion lasting 60 seconds elicited by bath application of NMDA and serotonin (5-HT) are shown. 
 
4.11 A₁ adenosine receptor modulation of chemically and electrically 
evoked lumbar locomotor network activity in isolated newborn rat spinal 
cords. 
See article attached. Taccola G, Olivieri D, D'Angelo G, Blackburn P, Secchia L, Ballanyi K.; 
Neuroscience 2012 
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CHAPTER 5: DISCUSSION 
5.1. L-AP4 neuroprotection against kainate induced excitotoxicity 
In previous experiments of our laboratory conducted by Taccola et al. (2004), L-AP4 was 
able to block strongly and reversibly synaptic transmission evoked by dorsal root stimulation 
and thus decreased spinal reflexes. The principal finding of this thesis is the novel 
demonstration that L-AP4, either co-applied with kainate or after washout, on a model of 
spinal cord injury is able to counteract excitotoxicity by reducing cell losses and the number 
of pyknotic nuclei. In particular, neuroprotecting motoneurons in the ventral part of the spinal 
cord organotypic cultures was an important observation, in connection with the high 
vulnerability of this cell type (Van Damme et al. 2002). These effects suggested that L-AP4 
was able not only to act as a spinal analgesic drug (Fisher et al. 2002; Mills et al. 2002b; 
Onaka et al. 1996), but also to have an effect on the levels of glutamate release and 
subsequent activation of postsynaptic pathways that lead to excitotoxicity. We can suggest 
that the activation of mGluR III group is similar to the one demonstrated in brain by Martin 
et al. (2007) modulating glutamate release by inhibiting P/Q-type Ca2+ channels and 
decreasing cAMP. Using both L-AP4 as an agonist and CPPG as an antagonist of the 
mGluR III group on organotypic spinal cord cultures, we suggest that these effects are 
related to the mGluR III group activation that are located in the pre-synaptic cleft (Niswender 
and Conn 2010). The decrease of the glutamate released in the synaptic cleft has a very 
important impact on the postsynaptic ionotropic glutamate receptor activation and 
contrasting kainate (0.1-0.5 mM) that strongly and rapidly increases extracellular levels of 
glutamate, a phenomenon that does not disappear with washout as demonstrated by 
Mazzone and Nistri, (2011b). Moreover, kainate binding to specific receptors leads to an 
increase in intracellular calcium levels leading to cell death phenomena in spinal cord (A. 
Kuzhandaivel, Nistri, and Mladinic 2010; A. Kuzhandaivel et al. 2011; G L Mazzone et al. 
2010): The mGluR III group activation seems to reduce the total increase of excitation 
probably through various different patterns. Deactivation of excitotoxic pathways is not only 
related to glutamate release, a recent work done by McMullan et al. (2010) shows that 
metabotropic glutamate receptors can inihibit microglial glutamate release, so probably  L-
AP4 neuroprotection is related, at least in part, to a similar cascade in our model too. . 
Furthermore, we investigated the role of mGluR III group antagonist CPPG that has been 
demonstrated to increase the damage related to kainate excitotoxicity by a strong 
deactivation of mGluR III group receptors. These findings underline the entanglement 
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between mGluR III group receptors and the modulation of the release of glutamate. The high 
neuroprotection of motoneurons in the ventral area can  suggest that different regions of the 
spinal cord differ for mechanisms underlying cell death becauset theh mGluR III group 
agonist L-AP4 seems to have a somewhat different extent of neuroprotection. Pizzi et al 
(1999) underlined neuroprotection by L-AP4 in motoneurons. suggesting that these neurons 
can be much more sensitive to this fine tuning by the mGluR III group receptor. Our model 
demonstrates that the neuroprotection by L-AP4 can be potentially helpful for future spinal 
cord injury treatments. Furthermore, the effect of CPPG suggests that during the excitotoxic 
damage exerted by kainate  there is an activation of mGluR III group receptor, but this 
activation is not enough to protect the cells from the harmful events related to kainate 
application. These events are presumably related to increased intracellular calcium and ionic 
imbalance (A. Kuzhandaivel et al. 2011; G L Mazzone and Nistri 2011). These  important 
effects are elicited by a relatively small concentration of L-AP4 (1 µM) that has been 
demonstrated have no toxic effect if used alone. All these results agree with previous data 
reported by Pizzi et al., (1999) and Tomiyama et al., (2001) comparing this secondary 
damage due to excitotoxicity to the neuronal degeneration typical of ALS These data, open 
further possibilities to study the relationship between SCI, traumatic or not, and other 
neurodegenerative diseases related of of the spinal cord. The present work not only is 
consistent with these observations but it also indicates that Ca2+ dependent and 
independent release mechanisms activated by kainate can be largely counteracted by the 
activation of mGluR III group receptors. Moreover, we can suggest that glutamate 
accumulating extracellularly actually has the potential to moderate its own action via 
activation of mGluR receptors, this can once more  be demonstrated by the increasing of 
cell death due to the CPPG presence. The different levels of neuroprotection in the different 
regions of interest seem not to be related to different type of localization of the different type 
of mGluR III subtypes. This result can be explained in two ways, the first is related to the 
type of analysis used, suggesting that a qualitative analysis such as the fluorescence signal 
intensity cannot detect small differences among the three subtypes of receptor; the other 
reason can be related to the specificity of the organotypic spinal cord cultures. The spinal 
cord cultures are characterized by a high number of neurons compared to other cell 
populations such as microglial cells or astrocytes: this high number of neurons might amplify 
the size of responses to treatments, but on the other hand it can mask relatively small 
differences like the metabotropic glutamate receptor distribution. The preliminary results 
using adenosine in co-application with L-AP4 suggest that the neuroprotection with mGluR 
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III group agonist probably reached a maximum level and cannot be increased by combined 
treatments with other substances. Moreover, considering that adenosine is able to shut 
down the rhythmic bursting at 2 mM concentration (G Taccola et al. 2012), probably an 
increase in the concentration of adenosine can induce multiple effects. These 
pharmacological results should be evaluated in future experiments using different 
concentrations of both adenosine and L-AP4 on organotypic spinal cord cultures or other 
types of spinal cord models. 
 
5.2. Neonatal spinal cord Isolated for 3 days in vitro  
Having a good model for studying long-term events after spinal cord injury is very important 
for the future of research (Akhtar et al. 2008). A model must follow 4 principles to be 
considered a good model: 1) simulate damage that is similar to clinical SCI; (2) control over 
conditions, reproducibility, stability; (3) involve a simple technique that is easy to study; (4) 
the equipment used to make a model is straightforward and quick to produce. Our results 
show that it is possible to maintain for at least 3 days in vitro an isolated spinal cord from 
neonatal rat and to possess a model that displays all 4 principles. Our model can be used 
to simulate damage (in particular excitotoxic damage) with high control over the 
experimental conditions. Having a significant number of samples allows a demonstration of 
a high reproducibility and stability of the model, and the whole process is very simple and 
easy to manage because it starts from previous models that are already used in spinal cord 
injury research such as the newborn isolated spinal cord. All these results can lead to new 
perspectives in the study of the role of late onset events after injury and this new model 
shows that in an oxygenated medium the isolated spinal cord suffers no damage and no 
events of necrosis and cell death after the dissection. Another important keypoint in the 
development of a good spinal cord model is the presence of electrical activity. Our model 
shows that not only electrical activity is maintained but also we are able to elicit the same 
pattern of responses using the same concentration of NMDA and 5-HT with fictive 
locomotion rhythm equal to the one elicited in freshly dissected newborn spinal cord. Having 
this model will help to analyze what happen in the late onset events at the central patter 
generator level, responsible of the fictive locomotion. The previous model has been 
important for understanding the basics of the spinal cord networks with or without injuries: 
we hope that another type of model can lead to other studies focusing on molecular biology 
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and electrophysiology of late-onset events. These new results can verify some of the 
findings that have been discovered withthe organotypic spinal cord cultures and give us a 
better understanding of the complex organization of the spinal cord tissue and networks. In 
future experiments we can analyze the role of mRNAs that can be translated after the initial 
injuries or other events related to changes in electrical activity during the first days of spinal 
cord injuries. 
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